SARS-COV-2

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

Retrieved on: 
Monday, November 13, 2023

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs). The program, developed with guidance from customers, funders, and market facilitators including the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply chain challenges.

Key Points: 
  • SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs).
  • "We know that enabling countries to perform pathogen sequencing locally strengthens health systems, enables better preparedness, and empowers countries to manage their priority health threats," said Vanessa Moeder, head of Global Health at Illumina.
  • In the Illumina global team's experience, Moeder says, the countries or regions whose public health preparedness would most benefit from genomics often lack the resources to sustainably implement it.
  • The equitable access program developed and operationalized by Illumina will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness."

Alliance Laboratories Debuts State-of-the-Art Lab Facility in Boca Raton, FL

Retrieved on: 
Wednesday, July 26, 2023

BOCA  RATON, Fla., July 26, 2023 /PRNewswire-PRWeb/ -- Alliance Laboratories, one of the leading independent CLIA-certified facilities focused on clinical and anatomic pathology in the Northeast, is pleased to announce the opening of a new laboratory and testing location in Boca Raton, Florida. As the demand for clinical blood, surgical pathology, cytopathology, toxicology, molecular and DNA testing services increases, the company is excited to expand its footprint to better serve their clients.

Key Points: 
  • "We are thrilled to announce our new lab in Boca Raton," said Richard Abrazi, Chief Executive and Chief Operating Officer of Alliance Laboratories, "Alliance Labs is committed to providing our partners and patients with the most rapid and reliable testing services.
  • The new Boca Raton location of Alliance Laboratories was previously known as University Pathology (UP Labs).
  • The Boca Raton facility operates as a full-service lab, focusing on surgical pathology and cytopathology.
  • For more information about the services provided by Alliance Laboratories or the new laboratory office location, please visit https://alliancelaboratories.com/ .

RS BioTherapeutics Announces Filing of Provisional Plant Patent Application for New Cultivar to Serve as Botanical Raw Material Source for First Compound

Retrieved on: 
Monday, May 1, 2023

RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.

Key Points: 
  • RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
  • Commenting on the provisional patent application Jeremy Plumb, Chief Cultivation Officer of RS BioTherapeutics said, “The filing of this provisional patent application is an important step as we proceed in the development of RSBT-001.
  • Beacon Hemp is dedicated to providing seed from innovative, stabilized and novel high cannabinoid hemp varieties through rigorous breeding and superior seed production.
  • An estimated 545 million people worldwide suffer from chronic respiratory diseases including asthma and COPD.

FactBid Launches 'AI Unfiltered Q&A' Podcast, Interviewing ChatGPT's AI Avatar for a Superhuman Analysis on Hot-Button Issues

Retrieved on: 
Tuesday, April 25, 2023

ChatGPT, a state-of-the-art artificial intelligence, provides a unique perspective that goes beyond what humans are capable of.

Key Points: 
  • ChatGPT, a state-of-the-art artificial intelligence, provides a unique perspective that goes beyond what humans are capable of.
  • The podcast explores today's most hot-button topics and delves into controversial issues, presenting a news-style interview format with an AI-generated Avatar representing ChatGPT.
  • To ensure that viewers receive ChatGPT's authentic and original answers, ChatGPT has created a code of ethics that FactBid will follow.
  • FactBid's "AI Unfiltered Q&A" is a must-listen for anyone interested in the cutting-edge of AI technology and its potential to revolutionize the way we think about complex issues.

Global Transport Media Market 2023 - 2028: Technological Advancement in Transport Media Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023

During the COVID-19 pandemic, several advancements and new products have been launched in the transport media market.

Key Points: 
  • During the COVID-19 pandemic, several advancements and new products have been launched in the transport media market.
  • In addition, the development of formulations and advanced designs for appropriate sample collection increased the adoption of transport media and delivered lucrative market growth opportunities.
  • In addition, the increased funding for infectious diseases diagnosis and growing research towards viral transport media due to the COVID-19 pandemic deliver lucrative opportunities for transport media market growth.
  • Most leading and emerging market players expand their manufacturing units with advanced facilities, expected to drive transport media market growth.

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Retrieved on: 
Wednesday, February 8, 2023

PALO ALTO, Calif., Feb. 8, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM). The study, which evaluated newly diagnosed outpatients with mild-to-moderate COVID-19, found that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events. The manuscript titled "Effect of Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients" will be published in the February 9, 2023 issue of NEJM and follows the topline safety and efficacy data announced March 17 2022.

Key Points: 
  • The treatment effect for peginterferon lambda was more pronounced in patients who were treated within 3 days of symptom onset.
  • Incidence of any treatment emergent adverse events was similar between peginterferon lambda and placebo groups, which were primarily injection site reactions.
  • "We have over 100,000 peginterferon lambda syringes readily available with additional manufacturing intermediates to support a capacity of >10 million units if needed.
  • In the context of our ongoing portfolio prioritization process, we continue to explore opportunities for ex-US emergency use of peginterferon lambda for COVID-19."

Fusion Genomics Establishes First-of-its-Kind Wastewater Surveillance Pilot Study at Toronto Airport

Retrieved on: 
Tuesday, January 10, 2023

Fusion Genomics announced today that the company has established a fully automated, first-of-its-kind infectious-disease surveillance facility at Toronto Pearson International Airport.

Key Points: 
  • Fusion Genomics announced today that the company has established a fully automated, first-of-its-kind infectious-disease surveillance facility at Toronto Pearson International Airport.
  • The pilot project, supported in part by funding from the National Research Council of Canada Industrial Research Assistance Program, is being facilitated by the Greater Toronto Airports Authority (GTAA).
  • Wastewater testing has been used to a small degree for infectious disease surveillance for years, but it was the COVID-19 pandemic that highlighted its extraordinary potential.
  • In a separate pilot study announced last year, Fusion Genomics deployed its ONETest Coronaviruses Plus test at Toronto Pearson to evaluate samples collected from passengers.

MTD GROUP: AN INNOVATIVE SAFETY NEEDLE WITH FULLY PASSIVE MECHANISM, RECEIVED FDA CLEARANCE

Retrieved on: 
Wednesday, January 11, 2023

Despite broad introduction of safety regulations over the last decades, it is estimated that more than 2 million NSIs still occur each year[1].

Key Points: 
  • Despite broad introduction of safety regulations over the last decades, it is estimated that more than 2 million NSIs still occur each year[1].
  • "Moving towards safer medical device technology –and especially evolving sharps with injury prevention features to a more passive design– promises to reduce needlestick injuries.
  • Safety device designs that require a user to actively do something can result in injury during activation, or failure to activate the safety feature at all.
  • A fully passive injection device such as the DropSafeTM SicuraTM, fulfills an unmet need of our customers in the US for increased safety.

MTD GROUP: AN INNOVATIVE SAFETY NEEDLE WITH FULLY PASSIVE MECHANISM, RECEIVED FDA CLEARANCE

Retrieved on: 
Wednesday, January 11, 2023

Despite broad introduction of safety regulations over the last decades, it is estimated that more than 2 million NSIs still occur each year[1].

Key Points: 
  • Despite broad introduction of safety regulations over the last decades, it is estimated that more than 2 million NSIs still occur each year[1].
  • "Moving towards safer medical device technology –and especially evolving sharps with injury prevention features to a more passive design– promises to reduce needlestick injuries.
  • Safety device designs that require a user to actively do something can result in injury during activation, or failure to activate the safety feature at all.
  • A fully passive injection device such as the DropSafeTM SicuraTM, fulfills an unmet need of our customers in the US for increased safety.

BiondVax CEO Issues Letter to Shareholders

Retrieved on: 
Friday, December 30, 2022

The letter reads as follows:

Key Points: 
  • The letter reads as follows:
    BiondVax’s 2022 achievements leave me incredibly optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders.
  • As compared to mAbs, NanoAbs being generated at MPI demonstrate several unique attributes such as greater binding affinity, stability at high temperatures, and formulation advantages.
  • We reported the successful first readout results in the preclinical in vivo study of our innovative inhaled COVID-19 NanoAb therapy.
  • I also want to thank our shareholders for their continued support as we progress toward our objectives.